CalciMedica Appoints Key Investor Evgeny Zaytsev to Board
CALC has more than doubled off its 52-week low of $0.461 on light trading volume (0.4× avg).
Summary
CalciMedica appointed Dr. Evgeny Zaytsev to its board, formalizing a key relationship following a significant $1.16 million investment by his affiliated fund in the company's recent private placement.
Key Events · Executive and Board Changes · CALC
-
New Director Appointed
Evgeny Zaytsev, M.D., Ph.D., was appointed as a Class I director, increasing the board size from seven to eight members.
-
Strategic Investor Joins Board
Dr. Zaytsev's appointment follows a significant $1.16 million investment by his affiliated fund in CalciMedica's recent private placement, signaling strong alignment and confidence.
-
Director Retirement Announced
Fred Middleton will retire from the board at the 2026 annual meeting, with the company stating his departure is not due to any disagreement.
-
Director Compensation
Dr. Zaytsev will receive an annual cash retainer of $40,000 and an option to purchase 20,000 shares of common stock, vesting over three years.
Analysis · CALC · Life Sciences
The appointment of Dr. Evgeny Zaytsev to the board is a significant positive development, as it formalizes a key relationship following a substantial $1.16 million investment by his affiliated fund in CalciMedica's recent private placement. This move strengthens governance and demonstrates significant financial commitment and confidence from a new board member, reinforcing the positive momentum from recent clinical trial results and capital raises. The retirement of Fred Middleton is routine and not due to any disagreements.
At the time of this filing, CALC was trading at $0.96 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.1M. The 52-week trading range was $0.46 to $7.20. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.